Jump to content
  • Dossier Advanced therapy medicinal products

    Novel gene and cell therapies are associated with high expectations in the treatment of incurable and hereditary diseases. Among them, CAR-T cell therapies have emerged as a major hope in cancer treatment.
    © BIOPRO Baden-Württemberg GmbH

  • Contact Stay in touch

    Would you like continue receiving e-mail notifications about our activities, up-to-date information, events, opportunities for cooperation and general industry information? Register here to stay informed about current issues.
    © denisismagilov / Adobe Stock

  • Industry report The healthcare industry in Baden-Württemberg

    BIOPRO's new report entitled "Healthcare Industry 2020: Facts and Figures for Baden-Württemberg" illustrates key figures like num the number of companies, number of employees and taxable turnover for the biotechnology, medical technology and pharmaceutical industry.
    © MR.LIGHTMAN / Adobe Stock

Latest news

  • Press release - 11/07/2024

    The "Friends of the German Cancer Research Center" association supports the DKFZ and aims to help strengthen its position in international competition. With the DKFZ Innovation Award presented at this year's DKFZ annual reception, the association honored Titus Brinker as a researcher whose highly innovative work builds a bridge from research to practical application with commercialization potential.

  • Press release - 10/07/2024

    HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the clinical candidate HRX-215.

  • TWYCE GmbH - 10/07/2024

    TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.

  • Press release - 05/07/2024

    With "OrgaPlexing", scientists at the MPI of Immunobiology and Epigenetics have developed a new method that shows how guardian cells of the immune system, the macrophages, orchestrate their cell structures during inflammation or bacterial infection, making it possible to observe the interactions between several organelles simultaneously and thus providing insights into cell metabolism and the production of inflammatory molecules.

Website address: https://www.gesundheitsindustrie-bw.de/en